Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2024-01-09 Sale | 2024-01-11 7:59 pm | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 7,417 | $20.14 | $149,367 | 78,614 (Direct) | View |
| 2024-01-02 Sale | 2024-01-04 6:06 pm | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,583 | $20.12 | $51,967 | 54,199 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-03-15 Option Award(A) | 2024-03-29 4:17 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 30,000 | $0 | 31,914 (Direct) | View |
| 2024-03-15 Option Award | 2024-03-18 7:28 pm | N/A 2034-03-14 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 90,000 | $0 | 91,914 (Direct) | View |
| 2024-01-09 Exercise | 2024-01-11 7:59 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 5,000 | $6.6 | 78,614 (Direct) | View |
| 2024-01-09 Exercise | 2024-01-11 7:59 pm | N/A 2030-01-22 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 7,417 | $0 | 78,614 (Direct) | View |
| 2024-01-09 Exercise | 2024-01-11 7:59 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,417 | $0.42 | 78,614 (Direct) | View |
| 2024-01-02 Exercise | 2024-01-04 6:06 pm | N/A 2030-01-22 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,583 | $0 | 54,199 (Direct) | View |
| 2024-01-02 Exercise | 2024-01-04 6:06 pm | N/A N/A | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 2,583 | $0.42 | 54,199 (Direct) | View |
| 2023-02-15 Option Award | 2023-02-17 7:19 pm | N/A 2033-02-14 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 62,200 | $0 | 62,200 (Direct) | View |
| 2022-05-12 Option Award | 2022-05-16 9:16 pm | N/A 2032-05-11 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 66,000 | $0 | 66,000 (Direct) | View |
Ownership | 2022-03-24 9:27 pm | N/A 2030-01-22 | AN2 Therapeutics Inc. | ANTX | Krause Kevin Michael Chief Strategy Officer | 0 | $0 | 141,174 (Direct) | View |